All News
Filter News
Found 806,088 articles
-
IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results
3/29/2023
IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022.
-
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
3/29/2023
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
-
Inimmune to Play a Key Role at the World Vaccine Congress on April 3-6, 2023
3/29/2023
Inimmune announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., and its Chief Operating Officer, David Burkhart, Ph.D., will play key roles at the World Vaccine Congress event.
-
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
3/29/2023
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023.
-
Lucius Partners Portfolio Company AerWave Medical, Inc. Announces it Has Filed Two New Patent Applications
3/29/2023
Lucius Partners, LLC ("LP"), today announced the filing of two new patent applications to the USPTO by its portfolio company AerWave Medical, Inc.
-
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results
3/29/2023
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022.
-
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
3/29/2023
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.
-
Decoding mRNA for Early Disease Detection, Treatment & Prevention
3/29/2023
Ludwig Enterprises, Inc. (OTC PINK:LUDG): Personalized genetic sequencing has taken a front seat in current healthcare attempts to optimize diagnosis and treatment of devastating diseases such as cancer, heart disease and stroke.
-
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023
3/29/2023
IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense System of minimally-invasive cryoablation technology that destroys tumors by freezing, today reported audited financial results as of and for the twelve months ended December 31, 2022.
-
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
3/29/2023
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update.
-
Massive Bio Accelerates Its Expansion in the European Union, Driven by New Clinical Trials Regulations
3/29/2023
Massive Bio, which uses artificial intelligence and concierge service to match cancer patients to oncology clinical trials regardless of their location or financial circumstances, continues its expansion beyond the United States.
-
OpGen Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/29/2023
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2022 and full-year 2022 financial and operating results and provided a business update.
-
CV Sciences, Inc. Reports Fiscal Year-End 2022 Financial Results
3/29/2023
CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we") today announced its financial results for the year and quarter ended December 31, 2022.
-
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/29/2023
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.
-
Cystic Fibrosis Foundation Announces Kathryn Brown as Next Chief Communications and Marketing Officer
3/29/2023
Today, the Cystic Fibrosis Foundation announced that Kathryn Brown will join the organization as its next Chief Communications and Marketing Officer.
-
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
3/29/2023
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced financial results for the year ended December 31, 2022, and recent business highlights.
-
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022
3/29/2023
Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022.
-
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
3/29/2023
Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full year ended December 31, 2022.
-
AmerisourceBergen Announces Date and Time for Second Quarter Fiscal 2023 Earnings Release
3/29/2023
AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter of Fiscal 2023 on Tuesday, May 2, 2023, prior to the opening of trading on the New York Stock Exchange.
-
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
3/29/2023
Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy for cancer presented proof-of-concept data from two sets of humanized mouse studies conducted independently by her laboratory at the University of California, Los Angeles (UCLA).